Page 108 - Read Online

Page 124 Gurule et al. Cancer Drug Resist 2018;1:118-25 I http://dx.doi.org/10.20517/cdr.2018.12

development to tumorigenesis. Differentiation 2007;75:770-87.
15. Suzuki H, Aoshiba K, Yokohori N, Nagai A. Epidermal growth factor receptor tyrosine kinase inhibition augments a murine model of
pulmonary fibrosis. Cancer Res 2003;63:5054-9.
16. Sakao S, Tatsumi K. Molecular mechanisms of lung-specific toxicity induced by epidermal growth factor receptor tyrosine kinase
inhibitors. Oncol Lett 2012;4:865-7.
17. Trusolino L, Bertotti A, Comoglio PM. MET signalling: principles and functions in development, organ regeneration and cancer. Nat
Rev Mol Cell Biol 2010;11:834-48.
18. Borowiak M, Garratt AN, Wüstefeld T, Strehle M, Trautwein C, Birchmeier C. Met provides essential signals for liver regeneration.
Proc Natl Acad Sci U S A 2004;101:10608-13.
19. Kroy DC, Schumacher F, Ramadori P, Hatting M, Bergheim I, Gassler N, Boekschoten MV, Müller M, Streetz KL, Trautwein C.
Hepatocyte specific deletion of c-Met leads to the development of severe non-alcoholic steatohepatitis in mice. J Hepatol 2014;61:883-90.
20. Brinkmann V, Foroutan H, Sachs M, Weidner KM, Birchmeier W. Hepatocyte growth factor/scatter factor induces a variety of tissue-
specific morphogenic programs in epithelial cells. J Cell Biol 1995;131:1573-86.
21. Agero AL, Dusza SW, Benvenuto-Andrade C, Busam KJ, Myskowski P, Halpern AC. Dermatologic side effects associated with the
epidermal growth factor receptor inhibitors. J Am Acad Dermatol 2006;55:657-70.
22. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, Jones CU, Sur R, Raben D, Jassem J, Ove R, Kies MS, Baselga J,
Youssoufian H, Amellal N, Rowinsky EK, Ang KK. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N
Engl J Med 2006;354:567-78.
23. Liu HB, Wu Y, Lv TF, Yao YW, Xiao YY, Yuan DM, Song Y. Skin rash could predict the response to EGFR tyrosine kinase inhibitor
and the prognosis for patients with non-small cell lung cancer: a systematic review and meta-analysis. PLoS One 2013;8:e55128.
24. Mohamed MK, Ramalingam S, Lin Y, Gooding W, Belani CP. Skin rash and good performance status predict improved survival with
gefitinib in patients with advanced non-small cell lung cancer. Ann Oncol 2005;16:780-5.
25. Petrelli F, Borgonovo K, Cabiddu M, Lonati V, Barni S. Relationship between skin rash and outcome in non-small-cell lung cancer
patients treated with anti-EGFR tyrosine kinase inhibitors: a literature-based meta-analysis of 24 trials. Lung Cancer 2012;78:8-15.
26. Pastore S, Lulli D, Girolomoni G. Epidermal growth factor receptor signalling in keratinocyte biology: implications for skin toxicity of
tyrosine kinase inhibitors. Arch Toxicol 2014;88:1189-203.
27. Mascia F, Mariani V, Girolomoni G, Pastore S. Blockade of the EGF receptor induces a deranged chemokine expression in keratinocytes
leading to enhanced skin inflammation. Am J Pathol 2003;163:303-12.
28. Ivashkiv LB, Donlin LT. Regulation of type I interferon responses. Nat Rev Immunol 2014;14:36-49.
29. Pollack BP, Sapkota B, Cartee TV. Epidermal growth factor receptor inhibition augments the expression of MHC class I and II genes.
Clin Cancer Res 2011;17:4400-13.
30. Kersh AE, Sasaki M, Cooper LA, Kissick HT, Pollack BP. Understanding the impact of ErbB activating events and signal transduction
on antigen processing and presentation: MHC expression as a model. Front Pharmacol 2016;7:327.
31. Pollack BP. EGFR inhibitors, MHC expression and immune responses: can EGFR inhibitors be used as immune response modifiers?
Oncoimmunology 2012;1:71-4.
32. Kumai T, Matsuda Y, Oikawa K, Aoki N, Kimura S, Harabuchi Y, Celis E, Kobayashi H. EGFR inhibitors augment antitumour helper
T-cell responses of HER family-specific immunotherapy. Br J Cancer 2013;109:2155-66.
33. Kumai T, Ohkuri T, Nagato T, Matsuda Y, Oikawa K, Aoki N, Kimura S, Celis E, Harabuchi Y, Kobayashi H. Targeting HER-3 to elicit
antitumor helper T cells against head and neck squamous cell carcinoma. Sci Rep 2015;5:16280.
34. Natalia J. Gurule NJ, McCoach C, Hinz TK, Marek L, Ryall K, Korpela S, Sisler D, Tan AC, Doebele RC, Heasley LE. Oncogene-
targeted agents induce and interferon response in EGFR and EML4-ALK driven lung cancer. In: Cancer Immunotherapy Combinations.
Montreal, Canada: Keystone Symposia; 2018.
35. Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E, Barlesi F, Kohlhäufl M,
Arrieta O, Burgio MA, Fayette J, Lena H, Poddubskaya E, Gerber DE, Gettinger SN, Rudin CM, Rizvi N, Crinò L, Blumenschein GR
Jr, Antonia SJ, Dorange C, Harbison CT, Graf Finckenstein F, Brahmer JR. Nivolumab versus docetaxel in advanced nonsquamous non-
small-cell lung cancer. N Engl J Med 2015;373:1627-39.
36. Gajewski TF, Corrales L, Williams J, Horton B, Sivan A, Spranger S. Cancer immunotherapy targets based on understanding the T cell-
inflamed versus non-T cell-inflamed tumor microenvironment. Adv Exp Med Biol 2017;1036:19-31.
37. Spranger S. Mechanisms of tumor escape in the context of the T-cell-inflamed and the non-T-cell-inflamed tumor microenvironment. Int
Immunol 2016;28:383-91.
38. Spranger S, Gajewski TF. Tumor-intrinsic oncogene pathways mediating immune avoidance. Oncoimmunology 2015;5:e1086862.
39. Ayers M, Lunceford J, Nebozhyn M, Murphy E, Loboda A, Kaufman DR, Albright A, Cheng JD, Kang SP, Shankaran V, Piha-Paul SA,
Yearley J, Seiwert TY, Ribas A, McClanahan TK. IFN-gamma-related mRNA profile predicts clinical response to PD-1 blockade. J Clin
Invest 2017;127:2930-40.
40. Moya-Horno I, Viteri S, Karachaliou N, Rosell R. Combination of immunotherapy with targeted therapies in advanced non-small cell
lung cancer (NSCLC). Ther Adv Med Oncol 2018;10:1758834017745012.
41. Ahn MJ, Yang HA, Saka H, Ramalingam SS, Goto K, Kim SW, Yang L, Walding AL, Oxnard GR. 136O - Osimertinib combined with
durvalumab in EGFR-mutant non-small cell lung cancer: results from the TATTON phase Ib trial. J Thorac Oncol 2016; doi: 10.1016/
S1556-0864(16)30246-5.
42. Rizvi NA, Chow LQM, Borghaei H, Shen Y, Harbison C, Alaparthy S, Chen AC, Gettinger SN. Safety and response with nivolumab